The life science group Sartorius, through its French listed subgroup Sartorius Stedim Biotech, has agreed to acquire 100 percent of Albumedix Ltd. from private investors. The Nottingham, UK-based company provides best-in-class recombinant albumin-based solutions. Recombinant human albumin is an important component for the biopharmaceutical industry required for various applications, for example as an animal-free additive to cell culture media and for the stabilization of vaccines and viral thera
At today's virtual Annual General Shareholders' Meeting, the shareholders of Sartorius AG granted discharge to the Executive Board and the Supervisory Board and approved the boards' proposals by a large majority. They passed the resolution to pay dividends of 1,26 euros per preference share and 1.25 euros per ordinary share. The total amount disbursed will be 85.9 million euros. In the previous year, dividends were 0.71 euros per preference share and 0.70 euros per ordinary share.
On the occasion of its virtual Annual General Shareholders' Meeting today, life science company Sartorius takes a positive look back at the past year and provides shareholders with details on further growth prospects. "Life sciences and the biopharmaceutical industry are currently in a very dynamic and innovative phase. Significant progress is being made at an increasing pace in the development of advanced therapies, such as cell and gene therapy methods, and mRNA technology is showing great pot